• F H Zhang, Y H Lin, H G Huang, J Z Sun, S Q Wen, and M Lou.
• Department of Neurology, The Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou 310009, People's Republic of China; Department of Neurology, The Affiliated Children's Hospital, Zhejiang University, School of Medicine, Hangzhou 310003, People's Republic of China.
• Neuroscience. 2013 Oct 10;250:651-7.

AbstractHemorrhagic transformation (HT) has been claimed to represent the most feared complication of treatment with intravenous tissue plasminogen activator (t-PA) therapy. In this study, we tested the effect of rosiglitazone on HT in a rat focal cerebral ischemia model. Male Sprague-Dawley rats received an injection of 50% dextrose (6ml/kg intraperitoneally) and were subjected to middle cerebral artery occlusion (MCAO) 10 min later, with the regional cerebral blood flow monitored in vivo by laser-Doppler-flowmetry. Two groups were included: rosiglitazone treatment and vehicle group. In the treatment group, after 1.5h of ischemia, rosiglitazone (2mg/kg) was administered at the onset of reperfusion. Neurobehavioral scores, infarct volume, hemoglobin leakage, hemorrhage rate, the expression of collagen IV and glucose transporter 1 (GLUT1) were measured at 24h after ischemia. Rosiglitazone improved neurobehavioral deficits, reduced infarct volume and hemorrhage rate, and inhibited hemoglobin leakage, when compared with the vehicle group. In addition, it increased the expression of collagen IV and GLUT1 compared to the vehicle group. Our results suggest that rosiglitazone attenuated the hyperglycemia-induced HT after MCAO, possibly by preservation of GLUT1 expression.Copyright © 2013 IBRO. Published by Elsevier Ltd. All rights reserved.

54 keywords...

hide…